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Background
Phosphodiesterase-5-inhibitors are vasoactive drugs used
in the treatment of erectile dysfunction and pulmonary
hypertension. Their beneficial effects in the pulmonary
vasculature are widely described, but it remained unclear,
how they influence cardiac performance. In the present
study we investigated the effects of the phosphodiesterase-
5-inhibitor vardenafil on myocardial and vasomotor
function in a rat model.
Methods
We performed left ventricular pressure-volume analysis in
young adult rats by using a Millar microtip conductance
catheter. Pressure-volume loops were recorded before and
after a single iv. injection of vardenafil (3, 10, 30, 100, 300
μg/kg, n = 6/group) and myocardial contractility parame-
ters (Emax (slope of ESPVR), PRSW, +dP/dt/EDV) were cal-
culated. Furthermore, in vitro organ bath experiments
with isolated aortic rings of the treated rats were per-
formed to investigate endothelium-dependent (using ace-
tylcholine) and -independent (using sodium
nitroprusside) vasorelaxation.
Results
Treatment with vardenafil resulted in a significant dose-
dependent increase in the load independent cardiac con-
tractility parameters reaching its maximum at the dose of
100 μg/kg (ESPVR: 2.15 ± 0.15 vs. 3.29 ± 0.26 mmHg/μl;
PRSW: 93.28 ± 4.04 vs. 134.90 ± 6.27 mmHg; +dP/dt/
EDV: 38.73 ± 7.97 vs. 53.02 ± 3.74 mmHg/s/μl, p < 0.05).
Results of in vitro organ-bath experiments showed a dose-
dependent improvement in the vasorelaxation of aortic
rings after vardenafil-treatment.
Conclusion
Our current results show that the phosphodiesterase-5-
inhibitor vardenafil improves myocardial contractility
and vasodilatory functions. Therefore it may represent a
novel therapeutic approach in the treatment of acute heart
failure.
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